Pharmaceutical company Pfizer on Thursday announced that a trial for their Omicron-specific booster vaccine, aimed at fighting infections caused by the BA.4 and BA.5 subvariants, has shown great promise.
The trial was only for adults.
Read the original article on Daily Maverick.
Daily Maverick is a unique blend of news, information, analysis and opinion delivered from our newsrooms in Cape Town and Johannesburg, South Africa. There are many ways to describe exactly what we do (and for the price of a cup of coffee we’re capable of talking your ears off about it), but the best way to understand the end result is to experience it. Every part of Daily Maverick is free-to-air and no payment is required, although free registration is required for a small subset of functions and pages.
Daily Maverick is run by an independently owned, private company with no affiliation to any other media group (or political party or religious organisation.) Follow Daily Maverick on Twitter at @dailymaverick.
Go to: https://www.dailymaverick.co.za/
